Literature DB >> 21826507

Utility of a novel pacing guidewire in pre-implantation testing at different left ventricular sites in cardiac resynchronization therapy procedures.

Ngai Yin Chan1, Chi Chung Choy, Chun Leung Lau, Ying Keung Lo, Pui Shan Chu, Ho Chuen Yuen, Suet Ting Lau.   

Abstract

PURPOSE: This study aimed to evaluate the utility of a novel pacing guidewire in pre-implantation testing of different left ventricular (LV) sites during cardiac resynchronization therapy (CRT) procedures.
METHODS: Ten consecutive patients (8 male, mean age 65.8 ± 4.9) undergoing CRT procedures were studied. Pacing threshold and R-wave sensing measured by the guidewire and LV lead at different LV sites were compared.
RESULTS: Thirty sites (6 apical, 13 middle, and 11 basal; 15 lateral and 15 anterior) were tested. There was significant correlation between pacing threshold (r = 0.878, p < 0.0001), and R-wave sensing (r = 0.896, p < 0.0001) obtained by guidewire and those obtained by LV lead. Separating into lateral and anterior sites, significant correlation was also found in pacing threshold (lateral r = 0.658, p = 0.008; anterior r = 0.886, p < 0.0001) and R-wave sensing (lateral r = 0.887, p < 0.0001; anterior 0.865, p < 0.0001). For basal and middle sites, significant correlation was found in pacing threshold (basal r = 0.890, p < 0.0001; middle r = 0.878, p < 0.0001), and R-wave sensing (basal r = 0.930, p < 0.0001; middle r = 0.823, p < 0.001). No and borderline correlation was found in pacing threshold (r = 0.548, p = 0.26) and R-wave sensing (r = 0.835, p = 0.039), respectively, for apical sites. Concordance rate for the presence of phrenic nerve stimulation at high pacing output was 87%.
CONCLUSION: The accuracy of the novel pacing guidewire in pre-implantation testing in CRT procedures is site-dependent. There was good correlation with LV lead in the measurement of pacing threshold and R-wave sensing at basal and middle sites, but not apical sites. Presence of phrenic nerve stimulation can be predicted by guidewire testing with high accuracy.

Entities:  

Mesh:

Year:  2011        PMID: 21826507     DOI: 10.1007/s10840-011-9602-0

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  17 in total

1.  Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure.

Authors:  Martin G St John Sutton; Ted Plappert; William T Abraham; Andrew L Smith; David B DeLurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Westby G Fisher; Myrvin Ellestad; John Messenger; Kristin Kruger; Kathryn E Hilpisch; Michael R S Hill
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

2.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

3.  Echocardiographic mapping of left ventricular resynchronization during cardiac resynchronization therapy procedures.

Authors:  Ngai-Yin Chan; Chi-Chung Choy; Kar-Chun Cheung; Chun-Leung Lau; Ying-Keung Lo; Pui-Shan Chu; Ho-Chuen Yuen; Suet-Ting Lau; Yuen-Choi Choi
Journal:  Chin Med J (Engl)       Date:  2010-07       Impact factor: 2.628

4.  Double wire technique to catheterize sharply angulated coronary sinus branches in cardiac resynchronization therapy.

Authors:  Gian-Battista Chierchia; Peter Geelen; Maximo Rivero-Ayerza; Pedro Brugada
Journal:  Pacing Clin Electrophysiol       Date:  2005-02       Impact factor: 1.976

5.  Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program.

Authors:  Angel R León; William T Abraham; Anne B Curtis; James P Daubert; Westby G Fisher; John Gurley; David L Hayes; Randy Lieberman; Susan Petersen-Stejskal; Kevin Wheelan
Journal:  J Am Coll Cardiol       Date:  2005-12-20       Impact factor: 24.094

6.  Effect of left ventricular lead concordance to the delayed contraction segment on echocardiographic and clinical outcomes after cardiac resynchronization therapy.

Authors:  Jeffrey W H Fung; Yat-Yin Lam; Qing Zhang; Gabriel W K Yip; Winnie W L Chan; Gary C P Chan; Joseph Y S Chan; Cheuk-Man Yu
Journal:  J Cardiovasc Electrophysiol       Date:  2008-11-21

7.  Usefulness of a pacing guidewire to facilitate left ventricular lead implantation in cardiac resynchronization therapy.

Authors:  Carel C de Cock; Jan C J Res; Matthijs L Hendriks; Cornelis P Allaart
Journal:  Pacing Clin Electrophysiol       Date:  2009-04       Impact factor: 1.976

8.  A new endocardial "over-the-wire" or stylet-driven left ventricular lead: first clinical experience.

Authors:  Sue Ellery; Vince Paul; Guenther Prenner; Karlheinz Tscheliessnigg; Bela Merkely; Klaus Malinowski; Gerd Fröhlig; Florian Hintringer; Olaf Bosse; Paolo Diotallevi; Antonio P Ravazzi; Horst Flathmann; Dejan Danilovic; Christina Unterberg-Buchwald
Journal:  Pacing Clin Electrophysiol       Date:  2005-01       Impact factor: 1.976

9.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

10.  Clinical experience of contrast venography guided axillary vein puncture in biventricular pacing.

Authors:  Ngai-Yin Chan; L Bing Liem; Ngai-Shing Mok; W Wong
Journal:  Int J Cardiol       Date:  2003-11       Impact factor: 4.164

View more
  1 in total

Review 1.  Phrenic nerve stimulation in cardiac resynchronization therapy.

Authors:  Ghassan Moubarak; Abdeslam Bouzeman; Jacky Ollitrault; Frederic Anselme; Serge Cazeau
Journal:  J Interv Card Electrophysiol       Date:  2014-06-17       Impact factor: 1.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.